LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Начало・Списък с акции・AbCellera Biologics Inc

AbCellera Biologics Inc

Затворен

СекторЗдравеопазване

4.23 1.44

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.09

Максимум

4.23

Ключови измерители
By Trading Economics
Приходи	11M -35M
Продажби	13M 17M
Марж на печалбата	-203.272
Служители	596
EBITDA	769K -39M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+118.01% upside

Дивиденти
By Dow Jones
Следващи печалби	3.11.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-46M 1.2B
Предишно отваряне	2.79
Предишно затваряне	4.23

Настроения в новините

By Acuity

61%

39%

325 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.99 / 2.635 Подкрепа & съпротива

AbCellera Biologics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

9.09.2025 г., 23:37 ч. UTC

Горещи акции

Stocks to Watch: Oracle, Wearable Devices, GameStop

9.09.2025 г., 20:41 ч. UTC

Печалби

Oracle's Backlog Surges With Major Customer Deals in 1Q

9.09.2025 г., 20:30 ч. UTC

Печалби

GameStop 2Q Sales, Profit Rise

9.09.2025 г., 23:19 ч. UTC

Пазарно говорене

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9.09.2025 г., 21:35 ч. UTC

Печалби

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9.09.2025 г., 21:32 ч. UTC

Печалби

Oracle's Backlog Swells With Big Customer Deals -- Update

9.09.2025 г., 21:02 ч. UTC

Придобивния, сливания и поглъщания

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.09.2025 г., 20:33 ч. UTC

Печалби

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9.09.2025 г., 20:26 ч. UTC

Печалби

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9.09.2025 г., 20:23 ч. UTC

Печалби

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9.09.2025 г., 20:12 ч. UTC

Печалби

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9.09.2025 г., 20:10 ч. UTC

Печалби

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9.09.2025 г., 20:10 ч. UTC

Печалби

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9.09.2025 г., 20:09 ч. UTC

Печалби

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9.09.2025 г., 20:09 ч. UTC

Печалби

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9.09.2025 г., 20:08 ч. UTC

Печалби

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9.09.2025 г., 20:08 ч. UTC

Печалби

Oracle 1Q Operating Income Was $4.3 B >ORCL

9.09.2025 г., 20:08 ч. UTC

Печалби

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9.09.2025 г., 20:08 ч. UTC

Печалби

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9.09.2025 г., 20:07 ч. UTC

Печалби

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9.09.2025 г., 20:06 ч. UTC

Печалби

Oracle 1Q Software Revenue $5.72B >ORCL

9.09.2025 г., 20:06 ч. UTC

Печалби

Synopsys 3Q Adj EPS $3.39 >SNPS

9.09.2025 г., 20:06 ч. UTC

Печалби

Oracle 1Q Cloud Revenue $7.19B >ORCL

9.09.2025 г., 20:05 ч. UTC

Печалби

Oracle 1Q Rev $14.93B >ORCL

9.09.2025 г., 20:05 ч. UTC

Печалби

Oracle 1Q EPS $1.01 >ORCL

9.09.2025 г., 20:05 ч. UTC

Печалби

Synopsys 3Q EPS $1.50 >SNPS

9.09.2025 г., 20:05 ч. UTC

Печалби

Oracle 1Q Services Revenue $1.35B >ORCL

9.09.2025 г., 20:05 ч. UTC

Печалби

Oracle 1Q Adj EPS $1.47 >ORCL

9.09.2025 г., 20:05 ч. UTC

Печалби

Oracle 1Q Hardware Revenue $670M >ORCL

Сравнение с други в отрасъла

Ценова промяна

AbCellera Biologics Inc Прогноза

Ценова цел

By TipRanks

118.01% нагоре

12-месечна прогноза

Среден 9.2 USD 118.01%

Висок 17 USD

Нисък 5 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за AbCellera Biologics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на AbCellera Biologics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.99 / 2.635Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Настроение

By Acuity

325 / 371 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.